---
title: "KELUN PHARMA: The company's products are expected to win bids in the 11th batch of national centralized drug procurement"
type: "News"
locale: "zh-CN"
url: "https://longbridge.com/zh-CN/news/263091491.md"
description: "KELUN PHARMA announced that the company and its subsidiaries participated in the bidding for the 11th batch of national centralized drug procurement, with plans to win bids for Maleate Aflibercept Tablets, Aflibercept Ethanolamine Tablets, Compound Sodium Acetate Ringer's Injection, and Agomelatine Tablets. The sales revenue for Aflibercept Ethanolamine Tablets in 2024 is expected to be 19.9423 million yuan, while the sales revenue for Compound Sodium Acetate Ringer's Injection is 17.7263 million yuan for 2023 and 7.9331 million yuan for 2024"
datetime: "2025-10-28T12:44:18.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/263091491.md)
  - [en](https://longbridge.com/en/news/263091491.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/263091491.md)
---

> 支持的语言: [English](https://longbridge.com/en/news/263091491.md) | [繁體中文](https://longbridge.com/zh-HK/news/263091491.md)


# KELUN PHARMA: The company's products are expected to win bids in the 11th batch of national centralized drug procurement

KELUN PHARMA announced that the company and its subsidiaries participated in the bidding work organized by the National Organization for Drug Procurement Office for the 11th batch of national centralized drug procurement. The company's products, Malate Avarbital Tablets, Avarbital Ethanolamine Tablets, Compound Sodium Acetate Ringer's Injection, and Agomelatine Tablets are expected to win bids. Among them, the sales revenue of Avarbital Ethanolamine Tablets for the year 2024 is expected to be 19.9423 million yuan, and the sales revenue of Compound Sodium Acetate Ringer's Injection for the year 2023 is expected to be 17.7263 million yuan, with a sales revenue of 7.9331 million yuan for the year 2024

### 相关股票

- [KELUN PHARMA (002422.CN)](https://longbridge.com/zh-CN/quote/002422.CN.md)

## 相关资讯与研究

- [Kelun-Biotech Sets March 2026 Board Meeting and Webcast for 2025 Results](https://longbridge.com/zh-CN/news/278713493.md)
- [06:47 ETKelun-Biotech and Harbour BioMed Announce NMPA Approval of IND Application for SKB575/HBM7575 for the Treatment of Atopic Dermatitis](https://longbridge.com/zh-CN/news/278376120.md)
- [Hengrui Pharmaceuticals Gets Nod to Trial SHR-9803 for Injection](https://longbridge.com/zh-CN/news/278830096.md)
- [SSY Gets China Nod for Production, Registration of Vitamin Injection](https://longbridge.com/zh-CN/news/279036594.md)
- [Cipla says U.S. unit to initiate recall of lanreotide injection](https://longbridge.com/zh-CN/news/278444171.md)